BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18983609)

  • 1. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Sierra J; Prat J
    Histopathology; 2008 Oct; 53(4):441-9. PubMed ID: 18983609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF-kappaB in peripheral T-cell lymphomas and is associated with clinical outcome.
    Briones J; Moga E; Espinosa I; Vergara C; Alvarez E; Villa J; Bordes R; Delgado J; Prat J; Sierra J
    Histopathology; 2009 Mar; 54(4):478-85. PubMed ID: 19309400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
    Ray DM; Morse KM; Hilchey SP; Garcia TM; Felgar RE; Maggirwar SB; Phipps RP; Bernstein SH
    Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
    Liu X; Wang B; Ma X; Guo Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
    Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
    Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma.
    Zhao Q; Fu W; Jiang H; Du J; Zhang C; Xi H; Zhou F; Li R; Hou J
    Hum Pathol; 2015 Apr; 46(4):524-31. PubMed ID: 25636172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of NF-kappaB by Toxoplasma gondii correlates with increased expression of antiapoptotic genes and localization of phosphorylated IkappaB to the parasitophorous vacuole membrane.
    Molestina RE; Payne TM; Coppens I; Sinai AP
    J Cell Sci; 2003 Nov; 116(Pt 21):4359-71. PubMed ID: 12966164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calbindin-D28K expression induced by glial cell line-derived neurotrophic factor in substantia nigra neurons dependent on PI3K/Akt/NF-kappaB signaling pathway.
    Wang HJ; Cao JP; Yu JK; Zhang LC; Jiang ZJ; Gao DS
    Eur J Pharmacol; 2008 Oct; 595(1-3):7-12. PubMed ID: 18703048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
    Seo SI; Song SY; Kang MR; Kim MS; Oh JE; Kim YR; Lee JY; Yoo NJ; Lee SH
    APMIS; 2009 Aug; 117(8):623-8. PubMed ID: 19664134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
    Guo RX; Qiao YH; Zhou Y; Li LX; Shi HR; Chen KS
    Pathol Int; 2008 Dec; 58(12):749-56. PubMed ID: 19067848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha.
    Lu ZG; Liu H; Yamaguchi T; Miki Y; Yoshida K
    Cancer Res; 2009 Jul; 69(14):5927-35. PubMed ID: 19549902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
    Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
    Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
    Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large B-cell lymphoma with Hodgkin's features.
    García JF; Mollejo M; Fraga M; Forteza J; Muniesa JA; Pérez-Guillermo M; Pérez-Seoane C; Rivera T; Ortega P; Piris MA
    Histopathology; 2005 Jul; 47(1):101-10. PubMed ID: 15982329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
    Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
    Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.